Guide / research peptides
What Are Research Peptides? Research Use vs. Approved Medications
“Research peptides” are peptide products sold with a label such as “for research use only” or “not for human consumption.” That label means the product was never reviewed for safety, effectiveness, purity, or sterility in people. Approved medications go through years of clinical trials and are made under inspected manufacturing standards. The two categories can share a molecule name, but they are not the same thing.
Last updated Medical review in progress
What a peptide is
A peptide is a short chain of amino acids, the building blocks of proteins. Many hormones the body makes are peptides, including insulin, GLP-1, and glucagon. Because peptides are fragile in the gut, most peptide medicines are given by injection.
Several widely used prescription drugs are peptides:
- Insulin for diabetes
- Semaglutide (Ozempic, Wegovy) for type 2 diabetes and weight management
- Tirzepatide (Mounjaro, Zepbound) for type 2 diabetes, weight management, and obstructive sleep apnea
- Teriparatide (Forteo) for osteoporosis
The word “peptide” describes the chemistry. It says nothing about whether a specific product is safe, approved, or legal to sell for human use.
What “research use only” actually means
Under federal law, whether a product is a drug depends on its intended use, not just its label. FDA has issued warning letters to sellers of peptides like semaglutide, tirzepatide, and retatrutide labeled “for research purposes” or “not for human consumption” and sold for people to use. FDA considers these illegal, unapproved drugs. A “research use only” label does not make a product legal or safe to inject.
The FDA’s statement has practical consequences:
- No clinical trials. The product was not tested in people for safety or effectiveness.
- No FDA review. Nobody at a regulator checked the dose, the purity, or the claims.
- No manufacturing standard for human use. Approved injectable drugs are made under current Good Manufacturing Practice (cGMP) rules that cover sterility, potency, and contamination. Research chemicals are not required to meet them.
- No label for patients. There is no prescribing information, no dose, no list of side effects, and no instructions for reconstitution or storage.
How this differs from an approved medication
| Feature | Approved medication | “Research use only” peptide |
|---|---|---|
| Tested in people | Yes, phase 1 to phase 3 trials | No |
| FDA review of safety and effectiveness | Yes | No |
| Manufacturing standard | cGMP, inspected | Not required for human use |
| Sterility and potency verified | Yes, batch by batch | Unknown |
| Prescribing information | Yes | None |
| Dispensed by | Licensed pharmacy | Online seller |
| Legal for human use | Yes, as prescribed | No |
Where compounded drugs fit
Compounded medications are a third category. A licensed pharmacy can make a drug for a specific patient under section 503A of the Federal Food, Drug, and Cosmetic Act, or in bulk under section 503B, when certain conditions are met. Compounded drugs are not FDA-approved, but they are made by licensed pharmacies from ingredients that must meet quality standards.
The FDA keeps a list of bulk substances it has evaluated for use in compounding. Several peptides that are popular in online “research” markets have been placed in the category of substances with significant safety risks, which means pharmacies are not permitted to compound them. The FDA has also stated that retatrutide, which is still in clinical trials, cannot be used in compounding under federal law.
Why the label matters for a molecule like semaglutide
The same peptide name can appear on an approved pen, a compounded vial, and a “research” vial. The FDA has reported dosing errors with compounded semaglutide, including patients who took 5 to 20 times the intended dose because of confusion between mg, mL, and syringe units. Those products at least came with a labeled strength. A research vial may not have a verified strength at all, so any dose math built on it is math built on a guess.
Questions to ask before trusting any peptide product
- Is it an FDA-approved product, a compounded product from a state-licensed pharmacy, or something else?
- Does it have prescribing information or a pharmacy label with a stated strength?
- Who made it, and under what manufacturing standard?
- Was it prescribed by a licensed clinician who knows your history?
If the answer to the first question is “something else,” the rest of the questions usually have no answer.
Common questions
Are research peptides legal?
Under federal law, intended use—not just the label—helps determine whether a product is a drug. FDA has warned sellers of semaglutide, tirzepatide, and retatrutide labeled for research or not for human consumption when they were sold for people to use. Those products are illegal, unapproved drugs.
Are research peptides the same as the approved drug with the same name?
No. The name describes the molecule the seller claims is in the vial. It does not tell you the purity, the actual amount, whether it is sterile, or whether it was ever tested in people.
Is a compounded peptide a research peptide?
No. Compounded drugs are made by licensed pharmacies under state and federal rules. They are not FDA-approved, but they are a regulated category. “Research use only” products are outside that system.
Can I get a peptide that is still in clinical trials?
Only by enrolling in a trial, or in rare cases through the FDA’s expanded access program. Products sold online as “research” versions of trial drugs are not the trial drug.
Keep reading
- 01Approved vs. investigational vs. research peptidesFour categories, who checks each one, and which can be used in people.
- 02What is retatrutide?Trial results, how it works, and where FDA approval stands.
- 03Units vs mL vs mgHow the three numbers relate, and the dosing errors the FDA reported.
- 04Dosing mistakesThe mix-ups the FDA has seen with compounded GLP-1s.
Sources
The medical and device facts on this page come from these sources. Each entry shows the date we accessed it.
- 01 FDA's concerns with unapproved GLP-1 drugs used for weight loss · U.S. Food and Drug Administration, 10/01/2026. Accessed 2026-10-01.
- 02 FDA alerts about dosing errors with compounded semaglutide · U.S. Food and Drug Administration, 07/26/2024. Accessed 2026-09-28.
- 03 Human Drug Compounding · U.S. Food and Drug Administration. Accessed 2026-09-30.
- 04 Development & Approval Process | Drugs · U.S. Food and Drug Administration. Accessed 2026-09-30.
- 05 Expanded Access · U.S. Food and Drug Administration. Accessed 2026-09-30.
- 06 Current Good Manufacturing Practice (CGMP) Regulations · U.S. Food and Drug Administration. Accessed 2026-09-30.
- 07 Federal Food, Drug, and Cosmetic Act, section 201(g): definition of “drug” (21 U.S.C. § 321) · Legal Information Institute, Cornell Law School. Accessed 2026-09-30.
- 08 Therapeutic peptides: current applications and future directions · Signal Transduction and Targeted Therapy, 2022;7:48. Accessed 2026-09-30.